Clinical Trial Update: An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese [Phase 2]

View source ↗

Summary

An open-label multicenter Phase 2 study evaluating maintenance Durvalumab (MEDI4736) plus Olaparib in Chinese patients with lung cancer and small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Olaparib (Olaparib)

Snippet

Sponsor: Li Zhang, MD | Conditions: Lung Cancer, Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN